Document Type
Article
Publication Date
12-30-2016
Abstract
Objective:
To determine whether patients who were newly prescribed antihypertensive therapy after the Eighth Joint National Committee (JNC 8) update were treated to a relaxed systolic blood pressure (SBP) goal compared with patients treated before the update.
Methods:
A retrospective cohort study approved by the Colorado Multiple Institutional Review Board. Patients aged 60–79 years, without diabetes or chronic kidney disease (CKD), newly treated for hypertension at a University of Colorado primary care clinics were included. The mean first-achieved and last-stable SBPs of patients newly prescribed antihypertensive medications from 1 January 2012 to 31 December 31 2013 (before cohort) were compared with patients newly prescribed antihypertensive therapy from 1 January 2014 to 1 October 2015 (after cohort). The mean number of antihypertensive medications at first-achieved SBP, the time to first-achieved SBP, and the class of initial antihypertensive medications were also evaluated.
Results:
A total of 128 patients were included, 64 patients in each cohort. The coprimary outcome of first-achieved mean SBP did not differ between the groups (131.3 mmHg versus 130.2 mmHg; p = 0.65). Last-stable mean SBP values were also similar between the groups (130.2 mmHg versus129.5 mmHg; p = 0.74). Angiotensin converting enzyme inhibitors (ACE-I) were the most frequently initiated antihypertensive agent in both cohorts (43.8% versus 48.4%; p = 0.72).
Conclusions:
Our findings suggest that the JNC 8 recommendations did not alter SBP goals among patients aged 60–79 years newly treated for hypertension at University of Colorado primary care clinics.
Recommended Citation
Kelly MS, Saseen JJ, Mars JC. Assessment of achieved systolic blood pressure in newly treated hypertensive patients aged 60-79 years before and after Eight Joint National Committee recommendations. Ther Adv Cardiovasc Dis. 2017;11(2):63-71. doi: 10.1177/1753944716684463
Copyright
The authors
Included in
Cardiovascular Diseases Commons, Circulatory and Respiratory Physiology Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutics and Drug Design Commons
Comments
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Therapeutic Advances in Cardiovascular Disease, volume 11, issue 2, in 2017 following peer review. The definitive publisher-authenticated version is available online at DOI: 10.1177/1753944716684463.